Found 6 matching trials
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) PHASE2 This study is a prospective, open-label, multicenter study in previously un...
Show More Location
The Affiliated Hospital of Xuzhou Medical University
Learn More & Join Trial
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma PHASE2 Assess the preliminary efficacy and safety of orelabrutinib in combination ...
Show More Location
Second Affiliated Hospital, School of Medicine, Zhejiang University
Learn More & Join Trial
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL N/A To retrospectively collect information on DLBCL patients treated with orela...
Show More Location
Hematological Department, People's Hospital of Jiangsu Province
Learn More & Join Trial
Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma PHASE2 This is a single-center, single-arm, prospective study aimed at evaluating ...
Show More Location
The First Bethune Hospital of Jilin University
Learn More & Join Trial
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation PHASE2 To evaluate the efficacy and safety of Genetic subtype-matched targeted the...
Show More Location
The First Affiliated Hospital of Soochow University
Learn More & Join Trial
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL NA To evaluate orelabrutinib in combination with polatuzumab vedotin, rituxima...
Show More Location
the First Affiliated Hospital of Xiamen University
Learn More & Join Trial